sodium lauryl sulfate
Sodium Lauryl Sulfate (SLS) is an anionic surfactant naturally derived from coconut and/or palm kernel oil. It usually consists of a mixture of sodium alkyl sulfates, mainly the lauryl. It is a widely used and inexpensive chemical found in many mainstream personal hygiene products such as shampoos, toothpastes, soaps, detergents and body wash. SLS is a detergent and surfactant, which essentially means that it breaks surface tension and separates molecules in order to allow better interaction between the product and your hair. It is also widely used as a skin irritant when testing products used to heal skin conditions. It was found that SLS represented a potential candidate for the use as a topical microbicide to prevent the sexual transmission of HIV-1, herpes, human papillomavirus and possibly other sexually transmitted pathogens. The mechanism of action of SLS involves the solubilization of the viral envelope and/or the denaturation of envelope and/or capsid proteins. — NCATS
Clinical trial activity
11 trials · 16 clinical orgs · 0 marketing orgs
Earliest trial started Jan 31, 2010 (NCT01501409)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetSurfactant
surfactant
Chemistry & pharmacology
SMILES
CCCCCCCCCCCCOS(O)(=O)=O- Mol. weight
- 266.397 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSodium dodecyl sulfate ↗
- NCATSDIQ16UC154 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05642702 | N/A | Dec 5, 2022 | Innovaderm, NovoBliss Research Pvt Ltd |
| NCT05260359 | Phase 2 | Feb 23, 2022 | DSM, Eurofins |
| NCT04942496 | Phase 4 | Jun 30, 2021 | Bio-Science Laboratories, Molnlycke Health Care AB |
| NCT04882631 | Phase 1 | Apr 13, 2021 | Pyramid Biosciences |
| NCT04534153 | Early Phase 1 (Phase 1) | Dec 31, 2020 | Food and Drug Administration, University of California, San Francisco |
| NCT04601103 | N/A | Jan 6, 2020 | 3M |
| NCT03833115 | N/A | Feb 23, 2018 | Laval University |
| NCT03502434 | Phase 1 | Sep 11, 2017 | Biosplice Therapeutics |
| NCT02615912 | N/A | Nov 30, 2015 | Kimberly Clark, RCTS, Inc. |
| NCT04531813 | Phase 3 | Jun 10, 2013 | Bayer |
| NCT01501409 | N/A | Jan 31, 2010 | Yonsei University |
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 3M | For profit | 1 | 1 | 1 | 2020 |
| Bayer | For profit | 1 | 1 | 1 | 2013 |
| Bio-Science Laboratories | For profit | 1 | 0 | 1 | 2021 |
| Biosplice Therapeutics | For profit | 1 | 1 | 1 | 2017 |
| DSM | For profit | 1 | 1 | 1 | 2022 |
| Eurofins | For profit | 1 | 0 | 1 | 2022 |
| Food and Drug Administration | Government | 1 | 0 | 1 | 2020 |
| Innovaderm | For profit | 1 | 0 | 1 | 2022 |
| Kimberly Clark | For profit | 1 | 1 | 1 | 2015 |
| Laval University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Molnlycke Health Care AB | For profit | 1 | 1 | 1 | 2021 |
| NovoBliss Research Pvt Ltd | For profit | 1 | 1 | 1 | 2022 |
| Pyramid Biosciences | For profit | 1 | 1 | 1 | 2021 |
| RCTS, Inc. | For profit | 1 | 0 | 1 | 2015 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2010 |